Patents by Inventor Cornelia OOSTVOGELS

Cornelia OOSTVOGELS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACID BASED COMBINATION VACCINES
    Publication number: 20220249654
    Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 7, 2022
    Publication date: August 11, 2022
    Applicant: CureVac AG
    Inventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
  • NUCLEIC ACID BASED COMBINATION VACCINES
    Publication number: 20220211841
    Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 7, 2022
    Publication date: July 7, 2022
    Applicant: CureVac AG
    Inventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
  • NUCLEIC ACID BASED COMBINATION VACCINES
    Publication number: 20220211838
    Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 7, 2022
    Publication date: July 7, 2022
    Applicant: CureVac AG
    Inventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
  • VACCINATION
    Publication number: 20210187098
    Abstract: Immunogenic compositions for use in and methods for protecting against Herpes Zoster (shingles).
    Type: Application
    Filed: April 27, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Cornelia OOSTVOGELS